Skip to main content

Table 1 Demographic and baseline characteristics of extension study groups at the start of the core study (safety population)

From: Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study

Parameter 200CONT (n = 64) 200CROSS (n = 33) 400CONT (n = 65) 400CROSS (n = 34)
Age, years, mean (SD) 53.2 (10.4) 52.4 (10.1) 52.1 (11.5) 52.1 (10.6)
Male sex, n (%) 63 (98.4) 33 (100) 60 (92.3) 32 (94.1)
Race, n (%)
 Asian 5 (7.8) 3 (9.1) 5 (7.7) 1 (2.9)
 Black or African American 9 (14.1) 4 (12.1) 8 (12.3) 1 (2.9)
 Māori 0 0 2 (3.1) 0
 White 48 (75.0) 26 (78.8) 49 (75.4) 31 (91.2)
Body mass index, kg/m2, mean (SD) 31.9 (5.9) 33.9 (6.1) 31.8 (5.8) 33.4 (5.9)
Duration since gout diagnosis, years, mean (SD) 15.8 (9.5) 13.8 (9.0) 12.9 (10.0) 12.0 (9.3)
Number of gout flares in past 12 months, mean (SD) 7.7 (13.6) 7.1 (5.8) 8.1 (8.2) 7.1 (5.9)
Type of gout flare prophylaxis, n (%)
 Colchicine 55 (85.9) 24 (72.7) 53 (81.5) 30 (88.2)
 NSAID 6 (9.4) 3 (9.1) 12 (18.5) 4 (11.8)
 Both 1 (1.6) 0 2 (3.1) 0
 Other/missing 4 (6.3) 6 (18.2) 2 (3.1) 0
sUA, mg/dl, mean (SD)
 At core study baselinea 5.4 (1.6) 4.9 (1.3) 5.0 (1.5) 5.3 (1.4)
 At extension study start 4.0 (2.2) 5.2 (1.7) 2.9 (1.7) 5.5 (2.4)
  1. Abbreviations: CONT Continuation of lesinurad treatment, CROSS Crossover from core study placebo to lesinurad treatment, NSAID Nonsteroidal anti-inflammatory drug, sUA Serum urate
  2. aFollowing 3 weeks of febuxostat 80 mg daily